Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03948191

99Tc-MDP for Thyroid-Associated Ophthalmopathy

Thyroid-Associated Ophthalmopathy Clinical Trial

Official title:
A Double-masked, Methylprednisolone-control, Efficacy and Safety Study of 99Tc-MDP for Thyroid Associated Ophthalmopathy.

Clinical Trial Summary

To investigate the efficacy，safety and tolerability of 99Tc-MDP in comparison to Methylprednisolone, in the treatment of participants suffering from active moderate to severe TAO.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03948191
Study type Interventional
Source Dalian University
Contact
Status Completed
Phase Phase 4
Start date October 16, 2017
Completion date March 31, 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT02693808 - New Treatment for Patients With Temporal Hollowing After Lateral Wall Decompression N/A
Completed NCT01599273 - Treatment of Upper Eyelid Retraction Related to Thyroid-associated Ophthalmopathy Using Subconjunctival Triamcinolone Injections Phase 4
Completed NCT01579539 - The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy Phase 3
Recruiting NCT02203682 - Doxycycline Treatment in Mild Thyroid-Associated Ophthalmopathy Phase 2
Completed NCT01868997 - Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease Phase 2
Terminated NCT00288522 - Lanreotide (Somatuline Autogel) in Thyroid-associated Ophthalmopathy Treatment Phase 2
Recruiting NCT04936854 - Sirolimus vs Corticosteroids in Treatment of Thyroid Eye Disease Phase 2
Completed NCT00595335 - Trial of Rituximab for Graves' Ophthalmopathy Phase 2/Phase 3